News - Respiratory and Pulmonary


Current filters:

Respiratory and Pulmonary

Popular Filters

151 to 175 of 360 results

Zambon to acquire UK respiratory specialist Profile Pharma


Family-owned Italian drugmaker Zambon has taken a significant step to grow in the respiratory therapy…

Mergers & AcquisitionsPharmaceuticalProfile PharmaPromixinRare diseasesRespiratory and PulmonaryZambon

AstraZeneca to pay up to $1.15 billion to acquire Pearl Therapeutics


In a further "strategic" bolt-on acquisition for Anglo-Swedish drug major AstraZeneca (LSE: AZN) in less…

AstraZenecaMergers & AcquisitionsPearl TherapeuticsPharmaceuticalPT003Respiratory and Pulmonary

Meda expands collaboration with India's Cipla on Dymista


Swedish drugmaker Meda (OMX: MEDA A) is broadening its collaboration with Indian pharmaceutical company…

Asia-PacificCiplaDymistaLicensingMedaPharmaceuticalRespiratory and PulmonaryRest of the WorldSouth America

Ockham Biotech prevails in Vectura's patent challenge for inhaled heparin in COPD


UK-based Ockham Biotech says that its European patent covering the use of inhaled heparin for the treatment…

BiotechnologyEuropeheparinOckham BiotechPatentsRespiratory and PulmonaryVectura

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort


US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

US Appeals Court puts temporary stop on sales of generics of AstraZeneca's Pulmicort Respules


Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last Friday (May 24) that the US Court of Appeals…

ActavisAstraZenecaGenericsLegalMarkets & MarketingNorth AmericaPharmaceuticalPulmicort RespulesRespiratory and Pulmonary

Grifols gains global rights to Aradigm's Pulmaquin


Spanish drugmaker Grifols (GRLS: MC) has signed an exclusive, worldwide license for USA-based Aradigm's…

Antibiotics and Infectious diseasesAradigmCiprofloxacinGrifolsLicensingMergers & AcquisitionsPharmaceuticalPulmaquinRespiratory and Pulmonary

Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations


French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN)…

BiotechnologydupilumabPharmaceuticalRegeneronResearchRespiratory and PulmonarySanofi

Stallergenes and DBV Technologies partner on developing novel respiratory allergies treatments


French biotech firms DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the treatment…

BiotechnologyDBV TechnologiesLicensingResearchRespiratory and PulmonaryStallergenes

Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member


German family-owned drug major Boehringer Ingelheim said today (May 17) that it is updating health care…

Boehringer IngelheimCombivent RespimatManagementPharmaceuticalProductionRespiratory and Pulmonary

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs


US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Vectura sets up JV, Kinnovata, for new respiratory business in China


UK-based developer of inhaled therapies Vectura (LSE: VEC) saw its shares rise 4.8% to 96.93 pence in…

Asia-PacificMergers & AcquisitionsPharmaceuticalProductionRespiratory and PulmonaryTianjin KingYorkTianjin Kinnovata PharmaVecturaZendex Bio Strategy

FDA approves Theravance and GSK's Breo Ellipta to treat COPD


The US Food and Drug Administration on Friday (May 10) approved Breo Ellipta (fluticasone furoate, an…

BiotechnologyBreo ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySkyepharmaTheravance Biopharma

Mixed results for Almirall and Forest's LAMA/LABA combo for COPD


Spain's largest drugmaker Almirall (ALM: MC) and US partner Forest Laboratories (NYSE: FRX) have announced…

aclidiniumAlmirallForest LaboratoriesformoterolPharmaceuticalResearchRespiratory and Pulmonary

Italy's Chiesi eyes Russian expansion


Privately held Italian drugmaker Chiesi Farmaceutici is considering a massive expansion into the Russian…

Chiesi FarmaceuticiEuropeGenericsMarkets & MarketingPharmstandardProductionRespiratory and Pulmonary

GlaxoSmithKline files for umeclidinium monotherapy approval in Europe


UK pharma giant GlaxoSmithKline (LSE: GSK) has submitted a regulatory application in the European Union…

BiotechnologyEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceumeclidinium

UK's NICE gives final guidance on Esbriet, Orencia and Xolair


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Positive new data on Novartis' once-daily QVA149 in COPD patients


Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showed that Swiss…

NovartisPharmaceuticalQVA149ResearchRespiratory and Pulmonary

GlaxoSmithKline and Theravance file for Japanese approval of Anoro Ellipta


UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) today April 22) announced…

Anoro ElliptaAsia-PacificGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

Merck & Co opens new $120 million manufacturing plant in China


US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

FDA advisory panel backs approval of COPD drug Breo Ellipta


Having earlier this week been presented with ambivalent briefing papers, the US Food and Drug Administration's…

Breo ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravance

Positive Ph III results for Almirall and Forest's combination COPD drug


Spain's largest pharma company Almirall (ALM: MC) and USA-based partner Forest Laboratories (NYSE:FRX)…

AlmirallBretaris GenuairEklira GenuairForest LaboratoriesPharmaceuticalResearchRespiratory and Pulmonary

USA FDA seeks clarification on Discovery Labs' Surfaxin; issues briefing papers on GSK's Breo Ellipta


US biotech firm Discovery Laboratories (Nasdaq: DSCO) says that the Food and Drug Administration has…

Breo ElliptaDiscovery LaboratoriesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySurfaxinTheravance

151 to 175 of 360 results

Back to top